Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

245 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein.
Janakiram M, Chinai JM, Fineberg S, Fiser A, Montagna C, Medavarapu R, Castano E, Jeon H, Ohaegbulam KC, Zhao R, Zhao A, Almo SC, Sparano JA, Zang X. Janakiram M, et al. Among authors: fineberg s. Clin Cancer Res. 2015 May 15;21(10):2359-66. doi: 10.1158/1078-0432.CCR-14-1495. Epub 2014 Dec 30. Clin Cancer Res. 2015. PMID: 25549724 Free PMC article.
Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer.
Sparano JA, Moulder S, Kazi A, Coppola D, Negassa A, Vahdat L, Li T, Pellegrino C, Fineberg S, Munster P, Malafa M, Lee D, Hoschander S, Hopkins U, Hershman D, Wright JJ, Kleer C, Merajver S, Sebti SM. Sparano JA, et al. Among authors: fineberg s. Clin Cancer Res. 2009 Apr 15;15(8):2942-8. doi: 10.1158/1078-0432.CCR-08-2658. Epub 2009 Apr 7. Clin Cancer Res. 2009. PMID: 19351752 Free PMC article. Clinical Trial.
Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma.
Andreopoulou E, Vigoda IS, Valero V, Hershman DL, Raptis G, Vahdat LT, Han HS, Wright JJ, Pellegrino CM, Cristofanilli M, Alvarez RH, Fehn K, Fineberg S, Sparano JA. Andreopoulou E, et al. Among authors: fineberg s. Breast Cancer Res Treat. 2013 Oct;141(3):429-35. doi: 10.1007/s10549-013-2704-x. Epub 2013 Sep 26. Breast Cancer Res Treat. 2013. PMID: 24068539 Free PMC article. Clinical Trial.
A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer.
Tu Y, Hershman DL, Bhalla K, Fiskus W, Pellegrino CM, Andreopoulou E, Makower D, Kalinsky K, Fehn K, Fineberg S, Negassa A, Montgomery LL, Wiechmann LS, Alpaugh RK, Huang M, Sparano JA. Tu Y, et al. Among authors: fineberg s. Breast Cancer Res Treat. 2014 Jul;146(1):145-52. doi: 10.1007/s10549-014-3008-5. Epub 2014 Jun 6. Breast Cancer Res Treat. 2014. PMID: 24903226 Clinical Trial.
A SOX9-B7x axis safeguards dedifferentiated tumor cells from immune surveillance to drive breast cancer progression.
Liu Y, John P, Nishitani K, Cui J, Nishimura CD, Christin JR, Couturier N, Ren X, Wei Y, Pulanco MC, Galbo PM Jr, Zhang X, Fu W, Cui W, Bartholdy BA, Zheng D, Lauvau G, Fineberg SA, Oktay MH, Zang X, Guo W. Liu Y, et al. Among authors: fineberg sa. Dev Cell. 2023 Dec 4;58(23):2700-2717.e12. doi: 10.1016/j.devcel.2023.10.010. Epub 2023 Nov 13. Dev Cell. 2023. PMID: 37963469
245 results